Targeting Cannabinoid 1 Receptor in Macrophages Alleviates Psoriatic Skin Inflammation Through the AUF1–NLRP3 Axis
Abstract
ABSTRACT Psoriasis is a chronic inflammatory skin disease associated with systemic metabolic dysregulation; however, the molecular pathways linking metabolic signaling to skin inflammation remain poorly understood. Here, we identify cannabinoid 1 receptor (CB1R) in macrophages as a key immunometabolic regulator of psoriatic inflammation and a potential therapeutic target. CB1R expression was increased in macrophages infiltrating psoriatic lesional skin in both humans and mice, and both pharmacological inhibition and genetic deletion of CB1R markedly attenuated psoriasis‐like pathology in mouse models by reducing epidermal hyperplasia, inflammation, and barrier dysfunction in a macrophage‐dependent manner. Mechanistically, CB1R signaling in macrophages suppressed expression of the RNA‐binding protein AUF1, leading to stabilization of Nlrp3 mRNA and enhanced NLRP3 inflammasome activation. AUF1 directly bound an AU‐rich region within the Nlrp3 3′ untranslated region and promoted mRNA destabilization, thereby limiting inflammasome activation and IL‐1β production. Restoration of AUF1 expression, either by CB1R inhibition or overexpression, reduced NLRP3 levels and alleviated psoriasis‐like pathology, whereas Nlrp3 deficiency abrogated these effects. Collectively, these findings define a CB1R–AUF1–NLRP3 signaling axis that links metabolic signaling to inflammasome‐driven skin inflammation in macrophages. Targeting macrophage CB1R may therefore represent a promising therapeutic strategy for psoriasis and other immunometabolic inflammatory diseases.